Granulomatosis With Polyangiitis Clinical Trial
Official title:
Phase I, Single-center, Randomized, Double-blind, Single-dose, Parallel Comparison of Pharmacokinetic and Safety Similarities Between Meperizumab Injection and NUCALA® in Healthy Male Volunteers
The trial was designed as a single-center, randomized, double-blind, single-dose parallel controlled phase I study to evaluate the similarity of pharmacokinetics and safety of Meperizumab injection and NUCALA® in healthy male volunteers. The plan is to enroll 88 healthy subjects. After signing the written informed consent voluntarily, the subjects will undergo a series of examinations and information collection to determine whether they meet the inclusion criteria. The qualified subjects will be randomized and administered. Biological samples were collected and safety checked before and after administration according to protocol requirements. Adverse events occurred during the trial were collected, and the combination of drug use and non-drug treatment were asked and recorded in detail. When the 90% confidence interval of geometric mean ratio of the main pharmacokinetic parameters of Meperizumab injection and NUCALA® was within the range of 80.00%-125.00%, it was proved that the pharmacokinetic characteristics of the two were similar.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01731561 -
Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
|
Phase 3 | |
| Completed |
NCT01862068 -
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)
|
||
| Completed |
NCT01750697 -
A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
|
Phase 2 | |
| Not yet recruiting |
NCT02126098 -
Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
|
N/A | |
| Terminated |
NCT01586858 -
Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
|
N/A | |
| Active, not recruiting |
NCT03919435 -
TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04871191 -
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
|
Phase 2 | |
| Terminated |
NCT05376319 -
PR3-AAV Resilient Remission or PRRR
|
Phase 2 | |
| Completed |
NCT02169219 -
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
|
Phase 4 | |
| Completed |
NCT01613599 -
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
|
||
| Active, not recruiting |
NCT05716334 -
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
|
||
| Recruiting |
NCT05703802 -
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.
|
||
| Recruiting |
NCT04944524 -
Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA
|
Phase 4 | |
| Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A | |
| Completed |
NCT03410290 -
Journey of Patients With Vasculitis From First Symptom to Diagnosis
|
||
| Recruiting |
NCT03482479 -
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
|
Phase 2 | |
| Active, not recruiting |
NCT01940094 -
The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach
|
Phase 3 | |
| Recruiting |
NCT01405807 -
Alemtuzumab for ANCA Associated Refractory Vasculitis
|
Phase 4 | |
| Active, not recruiting |
NCT01933724 -
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
|
Phase 3 | |
| Active, not recruiting |
NCT03967925 -
Rituximab and Belimumab Combination Therapy in PR3 Vasculitis
|
Phase 2 |